TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 0.5nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 0.5nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 0.600nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 0.710nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 0.800nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 0.800nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 0.800nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 0.850nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 0.900nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 0.900nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 0.910nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 0.980nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.10nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.10nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.10nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.10nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.10nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.10nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.20nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.20nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.20nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.20nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.20nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.20nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.20nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.30nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.30nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.30nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.30nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.30nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.30nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.30nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.30nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.40nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.40nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.40nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.40nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.40nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.5nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.5nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.5nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.5nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.5nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.5nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.5nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.60nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.60nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.60nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair